Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

COEP

Coeptis Therapeutics (COEP)

Coeptis Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COEP
DateTimeSourceHeadlineSymbolCompany
2:29PMiHub NewswireFeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership
09/05/20248:07AMPR Newswire (US)Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to ShareholdersNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/16/20244:02PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/16/20244:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/14/20245:26PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/14/20245:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
07/31/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
06/20/20248:47AMPR Newswire (US)Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
05/30/20248:47AMPR Newswire (US)Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
05/08/20248:47AMPR Newswire (US)Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
05/02/20248:47AMPR Newswire (US)Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
04/02/20248:47AMPR Newswire (US)Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardNASDAQ:COEPCoeptis Therapeutics Holdings Inc
02/26/20249:00AMPR Newswire (US)Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKNASDAQ:COEPCoeptis Therapeutics Holdings Inc
02/07/20247:30AMPR Newswire (US)Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
01/04/20247:30AMPR Newswire (US)Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
10/31/20239:01AMPR Newswire (US)Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023NASDAQ:COEPCoeptis Therapeutics Holdings Inc
10/24/20238:30AMPR Newswire (US)Coeptis Therapeutics Announces $2 Million Private PlacementNASDAQ:COEPCoeptis Therapeutics Holdings Inc
10/11/20237:30AMPR Newswire (US)Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
10/09/20239:15AMPR Newswire (US)Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
10/04/20237:30AMPR Newswire (US)Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
09/27/20237:30AMPR Newswire (US)Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaNASDAQ:COEPCoeptis Therapeutics Holdings Inc
09/14/20237:30AMPR Newswire (US)Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionNASDAQ:COEPCoeptis Therapeutics Holdings Inc
09/11/20237:30AMPR Newswire (US)Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/30/20231:00PMPR Newswire (US)Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/17/20237:30AMPR Newswire (US)Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/01/20238:00AMPR Newswire (US)Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticNASDAQ:COEPCoeptis Therapeutics Holdings Inc
06/16/20234:00PMPR Newswire (US)Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
06/14/20239:28AMPR Newswire (US)Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
06/09/20237:00AMPR Newswire (US)Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital MarketNASDAQ:COEPCoeptis Therapeutics Holdings Inc
05/17/20238:30AMPR Newswire (US)Coeptis Therapeutics Appoints Brian Cogley as Chief Financial OfficerNASDAQ:COEPCoeptis Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:COEP